Equities analysts expect DiaMedica Therapeutics Inc (NASDAQ:DMAC) to announce earnings of ($0.28) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for DiaMedica Therapeutics’ earnings. DiaMedica Therapeutics posted earnings per share of ($0.40) during the same quarter last year, which suggests a positive year over year growth rate of 30%. The company is expected to issue its next quarterly earnings report on Wednesday, September 4th.
On average, analysts expect that DiaMedica Therapeutics will report full-year earnings of ($0.85) per share for the current financial year. For the next year, analysts forecast that the business will report earnings of ($1.09) per share. Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for DiaMedica Therapeutics.
DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.05).
DMAC traded down $0.06 during trading on Friday, hitting $4.38. 2,582 shares of the stock were exchanged, compared to its average volume of 271,746. The stock has a 50 day moving average price of $3.73. DiaMedica Therapeutics has a 1 year low of $2.46 and a 1 year high of $5.93. The company has a quick ratio of 10.49, a current ratio of 10.49 and a debt-to-equity ratio of 0.01.
In related news, Director Richard D. Pilnik bought 19,000 shares of the company’s stock in a transaction on Friday, May 31st. The shares were acquired at an average price of $2.80 per share, with a total value of $53,200.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 12.80% of the company’s stock.
A hedge fund recently bought a new stake in DiaMedica Therapeutics stock. Wexford Capital LP purchased a new position in shares of DiaMedica Therapeutics Inc (NASDAQ:DMAC) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 475,000 shares of the company’s stock, valued at approximately $1,382,000. Wexford Capital LP owned approximately 3.97% of DiaMedica Therapeutics as of its most recent filing with the SEC. 8.48% of the stock is currently owned by institutional investors.
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications.
Further Reading: What are retained earnings?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.